Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis (ZTS) delivered earnings and revenue surprises of 13.64% and 2.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Beats Q3 Earnings and Revenue Estimates

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis reports third quarter 2021 financial results.

Zoetis Announces Third Quarter 2021 Results

Endo International

Moderna

Novavax

Regeneron Pharmaceuticals

Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?

Pfizer

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

Zoetis is the leader in pharmaceutical drugs, nutrition, and diagnostics for companion animals and livestock.

Zoetis: Expensive But Precision Livestock Farming Division Could Be Game Changer

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #ResearchandDevelopment--Robert J. Polzer, PhD, will succeed current EVP and President of R&D at Zoetis, Dr. Catherine Knupp, DVM, MS.

Zoetis Announces Appointment of Robert J. Polzer, PhD, as President of Research & Development for World Leader in Animal Health

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #dividend--The Board of Directors of Zoetis Inc. has declared a fourth quarter 2021 dividend payable to holders of the company's common stock of $0.25 per share.

Zoetis Declares Fourth Quarter 2021 Dividend

Johnson & Johnson

Here are two stocks to add to your basket of buys this fall.

Got $1,000? 2 Super-Smart Stocks That Could Make You Richer Over the Next Decade

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis Inc. will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021.

Zoetis to Host Webcast and Conference Call on Third Quarter 2021 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to present at the Jefferies Virtual Pet Care Summit on Thursday, Sept. 16th.

Zoetis to Participate in the Jefferies Virtual Pet Care Summit

Costco

Medtronic

PepsiCo

Republic Services

Instead of popular but volatile stocks, owning under-the-radar defensive gems will let you sleep at night.

6 Beautifully Boring Dividend Stocks

Amazon

Lockheed Martin

McDonald's

These seven stocks to buy right now for a bear market are also generally strong in bull markets. Their resistance is the key element.

7 Best Bear Market Stocks to Buy Now in Preparation for a Downturn

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Zoetis, Inc among others.

Zoetis, Inc Among This Week's U.S. Large Caps Stocks

Zoetis Inc. (NYSE: ZTS) reported its financial results for the second quarter on Thursday that beat Wall Street estimates. The stock was largely unbothered in after-hours trading despite raised guidance for the full year.

Zoetis CEO on Q2 results: “trends in companion animal are durable”

Zoetis Inc. (ZTS) CEO Kristin Peck on Q2 2021 Results - Earnings Call Transcript

Zoetis (ZTS) delivered earnings and revenue surprises of 10.19% and 6.30%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Surpasses Q2 Earnings and Revenue Estimates

Zoetis Inc. reported Thursday second-quarter profit and revenue that rose above expectations and lifted its full-year outlook, driven by petcare parasiticides, dermatology products, vaccines and diagnostics. The animal health company's stock slipped 0.4% in premarket trading, after closing Wednesday at a record.

Zoetis reported profit and revenue rose above expectations, raised the full-year guidance

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis reports second quarter 2021 results.

Zoetis Announces Second Quarter 2021 Results

Illumina

Novartis

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

PARSIPPANY, N.J. & RUTHERFORD, Australia--(BUSINESS WIRE)---- $ZTS #acquisition--Zoetis to acquire Jurox, a leading provider and manufacturer of livestock and companion animal products.

Zoetis to Acquire Jurox, a Leading Provider and Manufacturer of Livestock and Companion Animal Products

Bausch Health Companies Inc

Ironwood Pharma

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

Corcept Therapeutics

CORT vs. ZTS: Which Stock Is the Better Value Option?

CORT or ZTS: Which Is the Better Value Stock Right Now?

Ally Financial

Sierra Bancorp

First Busey

Dollar General

FS Bancorp

Gladstone Investment

Gladstone Investment Corporation - 6.375% PRF REDEEM 31/08/2025 USD 25 - Ser E

Gladstone Investment Corp 6 1/4% Cum Term Pfd Shs Series D

Gladstone Land

Morgan Stanley

Parke Bancorp

Riverview Bancorp

Star Group

Simpson Manufacturing

A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends.

Dividend Challenger Highlights: Week Of July 18

The stock price of Zoetis, an animal health company, has seen a 10% rise over the last twenty-one trading days, while it is up 40% over the last year. ZTS stock has benefited from an increased animal adoption in the U.S., which aided its sales for parasiticide products for companion animals.

News for Zoetis Stock (ZTS)